Trouble On The Line: Zimulti Shareholder Suit Fueled By Executive Comments On Earnings Calls
This article was originally published in The Pink Sheet Daily
Executive Summary
A district court reinstates a securities complaint against Sanofi involving its failed obesity drug.
You may also be interested in...
Obesity Drugs Face Tough Road To Approval Amid Fears Of Widespread Use
A matter of weeks away from the advisory committee review of the novel obesity drug lorcaserin, Arena's stock is flying high, yet the road to FDA approval, not to mention the daunting market, for obesity drugs looks more uncertain than ever